CRISPR-mediated Activation to Reduce Obesity

By UCSF on January 19, 2019
Catalyst awardees, Nadav Ahituv, PhD and Navneet Matharu, PhD, apply CRISPR-mediated activation to obesity. Here are the results:

Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines

January 04, 2019
- Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing - Brings together a portfolio of potential medicines and technologies - Led by Steve Harr, M.D. as CEO and Hans Bishop as Executive Chairman

Sana Biotechnology Launches

By UCSF on January 04, 2019
UCSF's Sonja Schrepfer helps found startup Sana Biotechnology, as they launch with a focus on engineering cells to create a new class of medicines.

Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

November 07, 2018
SAN DIEGO, November 6, 2018 – Fortis Therapeutics, Inc., an immuno-oncology biotech developing a novel antibody-drug conjugate (ADC) against CD46, today announced the U.S. Food and Drug Administration (FDA) has cleared two investigational new drug (IND) applications for the company’s lead candidate...

Venn Acquires Cancer Immunotherapy Antibody

By Press Release on April 23, 2018
Venn Therapeutics has completed an exclusive licensing deal with the University of California, San Francisco (UCSF) to advance its novel integrin αvβ8 antibody, created by a team of preeminent scientists at UCSF, led by Dr. Stephen Nishimura. Read More

Gilead Sciences and Kite to Acquire Cell Design Labs, One of UCSF Startups for $567 MM

December 07, 2017
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms...